VRBPAC endorsed mRNA-1010 for adults 50-64 and ≥65 years, unanimously concluding benefits outweighed risks, supporting a late-stage regulatory path toward potential first mRNA seasonal influenza ...

Older adults who face the highest rates of flu hospitalization moved one step closer to a new vaccine option on June 18, 2026 ...

CrowdStrike data and OpenAI's admission confirm prompt injection as a dominant enterprise AI attack vector. 65% of ...

Welcome, everyone. Thank you so much for joining us for this conversation about Moderna. My name is Courtney Breen. I am the U.S. pharma analyst here at Bernstein. And it is my privilege to have ...

Good day, and thank you for standing by. Welcome to Moderna's First Quarter 2026 Conference Call. [Operator Instructions] Please be advised, today's conference is being recorded. I would now like to ...

An alleged thief got more than he bargained for when a homeowner chased him down and made a citizen’s arrest overnight. Residents at a home on Ruby Ave were alerted by their home security system to ...

With an IPO raise of $625 million, Kailera Therapeutics now holds the new record for the largest public market debut. Biopharma opened the gates to the public markets in 1980—and first to go through ...

(Nanowerk Spotlight) As we close the final chapter of 2025, this Nanowerk Spotlight article marks a significant milestone in our coverage. We find ourselves standing at the midpoint of the decade: the ...

Moderna, already in cash-saving mode amid uncertain vaccine dynamics, is backing off from its plans to construct an mRNA drug substance plant in Japan. The vaccine maker opted to scrap the project ...

The remarkable commercial success of mRNA vaccines against COVID-19 and tumors, along with their potential as therapeutic drugs, has significantly boosted enthusiasm for circular RNAs (circRNA) as a ...